XML 83 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8
BioOne Acquisition
 12 Months Ended
Dec. 31, 2013
BioOne Acquisition

Note 3. BioOne Acquisition

On August 24, 2010, the Company acquired certain assets of BioOne, a privately held Japanese company established to develop technologies to improve the safety of blood products in Asia. The assets included the commercialization licenses that the Company had granted to BioOne for both the platelet and plasma systems, illuminators held as saleable inventory and demonstration illuminators. No liabilities were assumed.

The following table summarizes the fair value of assets acquired at the acquisition date (in thousands):

 

Commercialization rights—Asia

    $ 2,017   

Illuminators—inventory

      270   

Demonstration illuminators

      135   

Goodwill

      1,316   
  

 

 

  

Total

    $ 3,738   
  

 

 

  

The Company is amortizing the commercialization rights over a ten year period and annually evaluates the goodwill for impairment. See Note 8 for further information regarding the Company’s impairment analysis and the valuation of goodwill and intangible assets, net.

Certain illuminators acquired in connection with this transaction which remain unsold are classified as consigned equipment or demonstration equipment and reflected in property and equipment, net. See Note 7 for further information regarding the Company’s property and equipment, net.